Compare Samsara Inc (IOT) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Samsara Inc vs Natera Inc. Common Stock — how do they compare? Samsara Inc trades at $40.5 (market cap $24.17B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.4× Samsara Inc's market cap, and Samsara Inc is more actively traded (3,228,585 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Samsara Inc for 19 Days and Natera Inc. Common Stock for 0 Days on average.
| IOT | NTRA | |
|---|---|---|
Market Cap | $24.17B | $57.03B |
Volume | 3,228,585 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $45.22 | $425.64 |
52-Week Low | $24.25 | $179.42 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $23.41B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Samsara Inc. (IOT) trades at $41.27, down 0.84% today, with a bullish technical signal from moving averages and a consensus analyst price target of $51.15. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.20 versus $0.16 expected, and revenue growth of 30% year-over-year. Recent news highlights partnerships and product launches, including the Samsara MCP for AI integration and a rewards program for drivers.
The outlook is positive due to robust revenue growth, expanding large-customer base, and analyst optimism, but risks include high valuation multiples (P/E of 275.13) and cash flow pressures. Investment opportunity lies in continued execution and market share gains, while investors should monitor margin sustainability and competitive dynamics.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
